TTI

TETRA Technologies, Inc.
$9.48
+0.30 (+3.27%)
Mkt Cap 1.39B
Volume 1,746,142
52W Range 3.17-12.54
Sector Energy
Beta 1.19
EPS (TTM) 0.07
P/E Ratio 139.62
Revenue (TTM) 630.04M
Rev Growth (5Y) +10.8%
EPS Growth (5Y) N/A
AlphaVal · Fair Value
What we estimate one share is worth
$3.77
Overvalued strong signal
151.1% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C-
Oil & Gas E&P
50.8 / 100 composite
An oil & gas explorer and producer — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 630.93M 599.11M 626.26M 553.21M 388.27M 377.71M 561.24M 998.77M 723.10M 694.76M 1.13B 1.08B
Net Income 3.00M 108.28M 25.78M 7.84M (16.80M) (51.14M) (139.91M) (27.55M) (39.05M) (161.46M) (126.18M) (169.68M)
EPS 0.02 0.82 0.20 0.06 -0.13 -0.41 -1.11 -0.22 -0.34 -1.85 -1.59 -2.16
Free Cash Flow 19.54M (24.16M) 32.05M (21.10M) (15.88M) 47.53M (18.04M) (95.34M) 12.67M 32.91M 75.35M (22.96M)
FCF / Share 0.15 -0.18 0.25 -0.16 -0.13 0.38 -0.14 -0.77 0.11 0.38 0.95 -0.29
Operating CF 100.36M 36.52M 70.21M 18.96M 4.66M 76.91M 90.23M 46.59M 64.59M 53.98M 195.95M 108.64M
Total Assets 785.19M 718.58M 499.52M 457.59M 398.27M 1.13B 1.27B 1.39B 1.31B 1.32B 1.64B 2.07B
Total Debt 263.12M 221.39M 196.80M 194.15M 191.47M 246.26M 253.87M 842.58M 691.29M 700.82M 853.28M 935.03M
Cash & Equiv 44.99M 37.21M 52.48M 13.59M 31.55M 67.32M 15.40M 40.10M 26.39M 36.53M 29.78M 57.10M
Book Value 283.75M 254.57M 148.59M 107.62M 99.70M (9.64M) 34.37M 173.40M 208.08M 233.52M 241.22M 369.71M
Return on Equity 0.01 0.43 0.17 0.07 -0.17 N/A -4.07 -0.16 -0.19 -0.69 -0.52 -0.46
TTI News
TETRA TECHNOLOGIES, INC. ANNOUNCES DATE FOR SECOND QUARTER 2026 EARNINGS CONFERENCE CALL
Jul 13, 2026 12:00 PM · prnewswire.com
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome
Jul 13, 2026 02:00 AM · newsfilecorp.com
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
Jul 07, 2026 02:02 PM · seekingalpha.com
Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Jul 07, 2026 03:00 AM · globenewswire.com
Tetra Technologies (TTI) Soars 6.6%: Is Further Upside Left in the Stock?
Jun 29, 2026 11:10 AM · zacks.com
TETRA TECHNOLOGIES INTRODUCES TETRA NEPTUNE Z-LITE DEEPWATER COMPLETIONS FLUID
Jun 29, 2026 03:00 AM · prnewswire.com
TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript
Jun 24, 2026 09:32 AM · seekingalpha.com
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
Jun 17, 2026 04:00 AM · newsfilecorp.com
Can Viavi's New TETRA Testing Upgrade Strengthen Its Growth Story?
Jun 16, 2026 06:26 AM · zacks.com
VIAVI Launches TETRA MS Base Station Simulator Option for CX300 to Simplify and Speed Mission-Critical Radio Testing
Jun 15, 2026 02:30 AM · prnewswire.com